What is the significance of the supply agreement extension for Biome Australia (ASX:BIO)?

Biome Australia has extended its exclusive supply agreement with Probiotical SpA by two years, securing its supply chain through to 2028. This partnership is a foundation of Biome's operations, providing the "runway" needed for international expansion.

How does the Probiotical SpA deal affect Biome Australia’s (ASX:BIO) international strategy?

The extension acts as a primary driver for scaling Biome’s global footprint into markets like Canada, the United Kingdom, Ireland, and New Zealand. Since Probiotical is a vital strain partner, this agreement ensures Biome has the consistent pharmaceutical-grade inputs required to meet regulatory standards in these new regions.

What are the key commercial terms of the new Biome Australia (ASX:BIO) contract?

The new agreement maintains the existing commercial terms rather than introducing higher costs, which is a net positive for margins. The extension replaces a previous contract that was set to expire in June 2026, pushing the expiry out to 2028.

What is the "onshoring" program mentioned by Biome Australia (ASX:BIO)?

Biome is currently running an Australian manufacturing onshoring program designed to move production closer to its home market. This initiative aims to build domestic resilience and reduce reliance on long-distance logistics, which can be prone to external shocks.

What are the main bull and bear points for Biome Australia (ASX:BIO) after this news?

The bull case is centered on improved "earnings visibility" and a secured supply chain that supports aggressive 2028 growth targets. The bear case involves the inherent risk of high concentration on a single "vital strain partner" despite the contract extension.

Biome secures exclusive Probiotical supply extension through 2028

Written by Isaac FrancisPublished May. 12 2026Last Updated May. 12 2026

Biome Australia (ASX:BIO) solidified its long-term strategic foundation by executing a two-year extension to its exclusive supply agreement with Probiotical.

The pivotal renewal ensures that the partnership, which has been a cornerstone of Biome’s operations since its incorporation in 2018, will now continue through 2028.

By maintaining the existing commercial terms, the agreement provides the company with a stable and predictable "runway" to execute its ambitious international expansion across key markets, including Canada, the United Kingdom, Ireland, and New Zealand.

The extension replaces the previous contract, which was originally slated to expire in June.

Probiotical remains one of Biome’s most vital strain partners, and this continued collaboration is viewed as a primary driver for the company’s ability to scale its global footprint.

Beyond securing its international supply chain, Biome is simultaneously focused on domestic resilience through its Australian manufacturing offshoring programme.

The initiative, aimed at bringing production closer to home, is reportedly progressing well and remains a key pillar of the company’s broader supply chain strategy.

Investors and stakeholders can expect further transparency regarding these domestic developments, as Biome has committed to providing a comprehensive update on its Australian manufacturing progress within the 2026 calendar year.

At the time of reporting, Biome Australia’s share price was $0.28.